Register to receive a free U.S. Market Report Suite for Diagnostic Ophthalmic Devices – MedSuite report synopsis and brochure

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to participation, leading to a more nuanced understanding of ophthalmic diseases and potentially accelerating the development of novel treatments.

Data capture in traditional ophthalmic clinical trials can be inflexible and infrequent, making it difficult for researchers to monitor patients’ disease activity and capture real-world patient experiences. FocalView aims to help patients complete various assessments, gaining feedback on their visual function, including any changes over time. At the same time, the app could provide researchers with a greater volume of real-world, patient-reported data, creating more flexible and accessible clinical trial designs.

“Because patients with eye diseases are often not as mobile, FocalView has the potential to offer tremendous benefit for the ophthalmic community and for researchers looking to develop better treatments for these patients,” said Dr. Mark Bullimore, Medical Advisor for the creation of FocalView and Dean of the Southern California College of Optometry, Marshall B. Ketchum University. “Collating validated patient-reported outcomes in clinical trial research is no longer a nice-to-have. This kind of data is fast becoming a critical element of research and development, because it offers a better reflection of real-world patient experiences, fosters better patient compliance and provides researchers with richer and more accurate data points.”

FocalView will be tested in a prospective, non-interventional study to evaluate the app’s efficacy and usability in assessing visual function. These measurements include visual acuity and contrast sensitivity. Researchers will in turn assess ease of use, level of enrollment and the ability to obtain important documentation for future clinical trial research, such as informed consent. In the next phase, the app will be validated against traditional visual testing that takes place within conventional clinical settings.

“Optimizing digital technology in research and development, particularly in ophthalmic disease, could have a marked impact on the quality of the data we capture,” said Bertrand Bodson, Novartis Chief Digital Officer. “We believe apps like FocalView, which we’ve made freely available to the research community on an open-source platform, can help accelerate the development of treatments and bring them to the patients who need them most.”

FocalView is now available for download from the App Store in the US. Consent to contribute to research data will be required before a user can interact with the tool. Novartis is planning to launch in additional markets in the future.

Source: https://globenewswire.com/news-release/2018/04/25/1486792/0/en/Novartis-launches-FocalView-app-providing-opportunity-for-patients-to-participate-in-ophthalmology-clinical-trials-from-home.html

For Further Information

More on the interventional ophthalmic market in the U.S can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Diagnostic Ophthalmic Devices. The suite covers reports on the following markets: ophthalmic coherence tomography, fundus cameras, data management systems, slit lamps, perimeters, tonometers, autorefractors/keratometers, binocular indirect ophthalmoscopes, ophthalmic ultrasound devices, wavefront abberometers, corneal topographers, and optical biometers.

The iData report series on ophthalmic devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about ophthalmic device market data, register online or email us at [email protected] for a U.S. Market Report Suite for Diagnostic Ophthalmic Devices brochure and synopsis.